J
Jeanine L. Bussiere
Researcher at Amgen
Publications - 37
Citations - 4052
Jeanine L. Bussiere is an academic researcher from Amgen. The author has contributed to research in topics: Toxicity & Denosumab. The author has an hindex of 15, co-authored 37 publications receiving 3891 citations.
Papers
More filters
Journal ArticleDOI
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi,Roger Pai,Sharon Fong,Susan Leung,David A. Lawrence,Scot A. Marsters,Christine Blackie,Ling Chang,Amy E. McMurtrey,Andrea Hebert,Laura DeForge,Iphigenia Koumenis,Derf Lewis,Louise A. Harris,Jeanine L. Bussiere,Hartmut Koeppen,Zahra Shahrokh,Ralph H. Schwall +17 more
TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
David A. Lawrence,Zahra Shahrokh,Scot A. Marsters,Kirsten Achilles,Danny Shih,Barbara Mounho,Kenneth J. Hillan,Klara Totpal,Laura DeForge,Peter Schow,Jeffrey Hooley,Steve Sherwood,Roger Pai,Susan Leung,Lolo Khan,Brian Gliniak,Jeanine L. Bussiere,Craig A. Smith,Stephen S. Strom,Sean K. Kelley,Judith A. Fox,Deborah Thomas,Avi Ashkenazi +22 more
TL;DR: These findings not only provide a novel insight into the pathogenesis of the transplant-related atherosclerosis, but also point to a new therapeutic strategy that involves targeting of homing, differentiation and proliferation of putative smooth-muscle progenitor cells derived from the recipient.
Journal Article
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Sean K. Kelley,Louise A. Harris,David Xie,Laura DeForge,Klara Totpal,Jeanine L. Bussiere,Judith A. Fox +6 more
TL;DR: Estimates of Apo2L/TRAIL kinetics in humans were provided, suggesting that on a milligram per kilogram basis, doses significantly lower than those used in xenograft studies could be effective in humans.
Journal ArticleDOI
Developmental and reproductive toxicology studies in nonhuman primates.
Gary J. Chellman,Jeanine L. Bussiere,Norbert Makori,Pauline L. Martin,Yojiro Ooshima,Gerhard F. Weinbauer +5 more
TL;DR: Adequate designs in NHP are presented for developmental toxicity (embryo-fetal development, pre-postnatal development, enhanced pre- postnatal development), reproductive toxicity (male and female), and juvenile toxicity studies.
Journal ArticleDOI
Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals:
Jeanine L. Bussiere,Pauline L. Martin,Michelle Horner,Jessica Couch,Meghan M. Flaherty,Laura Andrews,Joseph Beyer,Christopher J. Horvath +7 more
TL;DR: Alternative approaches, including animal models of disease, genetically modified mice, or use of surrogate molecules, may improve the predictive value of preclinical safety assessments of species-specific biopharmaceuticals, although many caveats associated with these models must be considered.